However, it is noteworthy that studies of other preclinical TB vaccines have shown abrogation of specific CD8+ T cell responses and even long-term protection against Mtb, if the order of a protein-adjuvant prime and respective DNA (76) or viral vector (77) boost is reversed. Here, CD8A is linked to tuberculosis.